Cargando…

Resource utilization and cost saving analysis of subcutaneous versus intravenous trastuzumab in early breast cancer patients

We conducted an economic evaluation of intravenous (IV) vs subcutaneous (SC) trastuzumab for the treatment of patients with early breast cancer (EBC). Data of patients receiving adjuvant IV trastuzumab at our institute in 2014 were used to study three different treatment scenarios: 1) IV trastuzumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farolfi, Alberto, Silimbani, Paolo, Gallegati, Davide, Petracci, Elisabetta, Schirone, Alessio, Altini, Mattia, Masini, Carla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655288/ https://www.ncbi.nlm.nih.gov/pubmed/29113393 http://dx.doi.org/10.18632/oncotarget.18527

Ejemplares similares

The Challenge of Sustainability of High-Cost Oncological Drugs: A Budgeting Model in an Italian Cancer Center
por: Masini, Carla, et al.
Publicado: (2021)

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
por: Waller, Cornelius F., et al.
Publicado: (2021)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey
por: Ponzetti, Clemente, et al.
Publicado: (2016)

Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey [Corrigendum]
Publicado: (2017)

Stability of calcium levofolinate reconstituted in syringes and diluted in NaCl 0.9% and glucose 5% polyolefin/polyamide infusion bags
por: Sanogo, Seydou, et al.
Publicado: (2020)

Assessment of Cancer Care Costs in Disease-Specific Cancer Care Pathways
por: Altini, Mattia, et al.
Publicado: (2020)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
por: Lopez-Vivanco, G., et al.
Publicado: (2017)

Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings?
por: Kassem, Loay, et al.
Publicado: (2019)

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives
por: Papadmitriou, K., et al.
Publicado: (2015)

Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
por: Rojas, Luis, et al.
Publicado: (2020)

The smooth and bumpy road of trastuzumab administration: from intravenous (IV) in a hospital to subcutaneous (SC) at home
por: Tjalma, WAA, et al.
Publicado: (2017)

Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study
por: Abad-Sazatornil, María Reyes, et al.
Publicado: (2021)

A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER2‐positive early breast cancer
por: De Cock, Erwin, et al.
Publicado: (2016)

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
por: Jackisch, Christian, et al.
Publicado: (2022)

Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
por: De Cock, Erwin, et al.
Publicado: (2016)

The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review
por: Van den Nest, Miriam, et al.
Publicado: (2019)

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases
por: Matza, Louis S, et al.
Publicado: (2013)

On the Subcutaneous Injection of Blood, Infusion (Subcutaneous) and Intravenous Transfusion
por: Oehler,, et al.
Publicado: (1888)

Quality of care in the course of subcutaneous versus intravenous trastuzumab administration in patients with breast cancer: an integrated time–motion study with mixed-methods research
por: Lin, Hsiang-Wen, et al.
Publicado: (2023)

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase
por: Shpilberg, O, et al.
Publicado: (2013)

Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab
por: Pimentel, Franklin Fernandes, et al.
Publicado: (2018)

A Cost-Saving Hemodialysis Scheme in Limited-Resource Settings
por: Aoun, Mabel
Publicado: (2022)

Greening the office: Saving resources, saving money, and educating our patients
por: Blum, Stacy, et al.
Publicado: (2020)

Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients
por: Massa, Ilaria, et al.
Publicado: (2018)

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
por: McCloskey, Conor, et al.
Publicado: (2022)

Setting Up a Medical Oncology Educational Program in Sub-Saharan Africa
por: Bravaccini, Sara, et al.
Publicado: (2021)

Influenza vaccination in breast cancer patients during subcutaneous trastuzumab in adjuvant setting
por: Joona, Therse Björkin, et al.
Publicado: (2020)

Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
por: Delgado Sánchez, Olga, et al.
Publicado: (2019)

Resource Use Following Atrial Fibrillation Ablation: Spending Resources to Save Resources
por: Zeitler, Emily P., et al.
Publicado: (2023)

Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer
por: Quartino, Angelica L., et al.
Publicado: (2015)

Higher Doses of Subcutaneous IgG Reduce Resource Utilization in Patients with Primary Immunodeficiency
por: Haddad, Elie, et al.
Publicado: (2011)

Health Resource and Cost Savings Achieved in a Multidisciplinary Lung Cancer Clinic
por: Stone, Christopher J. L., et al.
Publicado: (2021)

Preference for Subcutaneous Injection or Intravenous Infusion of Biological Therapy Among Italian Patients With SLE
por: Falanga, Marina, et al.
Publicado: (2018)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study
por: North, Richard T, et al.
Publicado: (2015)

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA
por: Ades, Felipe, et al.
Publicado: (2017)

Administrative risk quantification of subcutaneous and intravenous therapies in Italian centers utilizing the Failure Mode and Effects Analysis approach
por: Ponzetti, Clemente, et al.
Publicado: (2016)

Indonesia-Based Study of the Clinical and Cost-Saving Benefits of Subcutaneous Allergen Immunotherapy for Children with Allergic Rhinitis in Private Practice
por: Endaryanto, Anang, et al.
Publicado: (2021)

Saving Limited Resources During Covid-19 Pandemic
por: Piazza, O
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ohn6tj8unefk19k9faj2gpfptu